biOasis Technologies Ord Shs V.BTI.H

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The recent Option Grant.

[prophetoffactz]

"I think a financing is not for the CRES101 clinical trial. I think the financing is for pocket money, engaging CRES101 clinical trial sites, and to allow Ladenburg Thalmann clients to wet their beaks on the Bioasis project."

Ideally BTI has enough money for 12 months or more or to get to key catalysts; especially in a dramatic risk-on/risk-off market like we've been in or investors may be worried about the next financing and if we hit a risk-off market. We live in a very unstable and risky world for financial assets right now. Mark Day wanted to raise US$10 million in his NASDAQ pursuit and to advance Herceptin and the broader pipeline. Rathjen wants to advance two EGF indications into clinical trials in the next approximately nine months for which it may have to wait one year for key data. Rathjen also wants to initiate the Hunter clinical trial by the end of next year and has the broader xB3 pipeline and partners to support. 

It would be nice to finally get the financial risk off the table for the next 1 1/2 years or more  so that the market can have a clear line of sight to the next major catalysts in this very risky world. So much time has been wasted by this company living a hand-to-mouth financial existence and being radically undercapitalized as it stumbles along. This company needs to look like its in business in the next 12-24 months and not at risk of going broke. It needs to be 100% focused on advancing the science.

There are a number of deals that can help build cash and validate xB3 near term.